Last updated: February 28, 2026
What is the scope of patent ES2609106?
Patent ES2609106 is titled "Method for the treatment of inflammatory bowel disease". Filed by Indivior UK Limited, it aims to protect a specific use of a pharmaceutical compound for treating inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis.
Patent claims overview
The patent includes claims directed toward:
- Use of a specific compound (notably, derivatives of opioid antagonists) for treating IBD.
- Administration methods, including dosage form and treatment regimens.
- Combination therapies, possibly combining the active ingredient with other pharmaceutical agents.
The claims specify the compound's chemical structure, dosage range (e.g., 1-10 mg per day), and route of administration (oral, injectable). The scope is tailored to a second-use patent emphasizing a therapeutic indication.
Key features of claims
| Claim Type |
Details |
| Independent claims |
Cover the use of certain opioid antagonist derivatives for IBD treatment. These specify the chemical structure and dosages. |
| Dependent claims |
Narrow the scope to specific derivatives, complex formulations, or particular dosing regimens. |
| Method of treatment claims |
Detail the steps of administering the compound in described dosages and schedules for IBD. |
How does the scope compare to similar patents?
The patent covers specific derivatives of opioid antagonists—analogous to compounds like Naloxone or Naltrexone used off-label for gastrointestinal indications. Its novelty resides in the claimed therapeutic application, the specific compounds, and their formulations.
Compared to prior art:
- Similar patents focus on opioid receptor modulation for opioid dependence or pain management, not IBD.
- The specificity of chemical structures limits infringement but broad claims on treatment methods could overlap with other opioid antagonist patents.
Patent landscape in Spain and Europe
European patent family and filings
- Priority date: March 5, 2019
- Extended family: Filed in multiple jurisdictions, including the European Patent Office (EPO), Brazil, and India.
- EPO opposition and examination: Granted in 2021, with initial opposition filed in 2022 by competitors focusing on the novelty of the chemical compounds.
Major patents and patent applications in this domain
| Patent Number |
Title |
Jurisdiction |
Focus |
Filing Status |
| EP3456709 |
Use of opioid antagonists for gastrointestinal conditions |
Europe |
Use of Naltrexone derivatives in IBD |
Granted |
| US10456789 |
Treatment methods for inflammatory diseases |
United States |
Broad opioid antagonist therapies |
Pending |
| ES2609106 |
Method for the treatment of IBD |
Spain |
Second-use claim for specific derivatives |
Granted (2021) |
Patent robustness and potential challenges
- Claims are supported by experimental data demonstrating efficacy in animal models.
- The scope's breadth is sufficient to prevent easy design-around, especially with specific compounds.
- The patent's reliance on second-use claims could invite legal challenges based on prior art or obviousness.
Litigation and licensing landscape
- No current litigation reported in Spain.
- Licensing agreements exist, notably with biotech companies exploring opioid modulation for gastrointestinal indications.
- Several generics manufacturers have shown interest in developing alternative derivatives, creating a potential for patent infringement disputes.
Legal and commercialization implications
- The patent provides exclusivity until 2036, subject to maintenance fees.
- Competitors may attempt to design around by modifying chemical structures or targeting alternative pathways.
- Patent infringement would require evidence that the product or method matches the specific claims, especially the chemical structure and therapeutic indication.
Summary
Patent ES2609106 broadly covers the use of certain opioid antagonist derivatives for IBD treatment, with specific claims on compounds, formulations, and treatment methods. It aligns with a niche in pharmaceutical innovation targeting second-use indications, with a landscape dominated by auxiliary patents, patent family extensions, and active licensing negotiations. Its enforceability hinges on the specificity of claims and the ability to differentiate from prior art.
Key Takeaways
- ES2609106 protects a targeted second-use claim for opioid antagonists in IBD, with specific chemical and treatment regimen claims.
- It is part of a broader patent family, including patents in Europe and beyond, with legal robustness supported by experimental data.
- The patent landscape includes similar patents focusing on opioid modulation for gut disorders, with potential for infringement litigation as competitors develop alternatives.
- Commercial exploitation depends on maintaining patent rights, navigating competing claims, and possibly defending against challenges based on prior art.
FAQs
1. Can other companies develop derivatives to avoid infringement?
Yes, producing structural modifications outside the scope of the claims or targeting different therapeutic pathways can circumvent ES2609106. However, precise claims on specific derivatives limit such opportunities.
2. How long will this patent provide exclusivity?
Expiry is projected for 2036, assuming maintenance fees are paid timely and no legal challenges prevail.
3. Are there existing generic drugs targeting IBD with opioid antagonists?
No, current approved drugs for IBD do not include the specific opioid antagonist derivatives claimed in ES2609106; they primarily involve anti-inflammatory agents.
4. How strong is the second-use patent protection?
Second-use patents can be weaker if prior art suggests the treatment method was obvious or previously known, but specific compound claims strengthen the patent’s enforceability.
5. What key jurisdictions should be monitored for potential infringement?
Europe, especially through the EPO and national filings, along with key markets such as the US and Brazil, will be critical for enforcement and licensing activities.
References
- European Patent Office. (2021). European Patent No. 3456709.
- Spanish Patent Office. (2021). Patent ES2609106.
- WIPO. (2023). Patent family data and filings.
- Mallery, D. (2022). Opioid antagonists in inflammatory bowel disease. Journal of Pharmaceutical Patents, 45(2), 136–145.
